☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
non-small cell lung cancer (NSCLC)
AstraZeneca's Imfinzi (durvalumab) New Dosing Option Receives Approval for NSCLC in the EU & UK
January 18, 2021
AstraZeneca Reports Results of Imfinzi (durvalumab) & Tremelimumab in Global P-III MYSTIC Trial for Stage IV Non-Small Cell Lu...
November 19, 2018
Load more...
Back to Home